This Flying-Under-the-Radar Pharma Stock Pays Nearly 7% (While Everyone's Sleeping)

Key Points The end of a short-lived, COVID-related revenue surge has brought Pfizer's stock lower. But sellers have ignored all the developmental work this pharma icon has going on. At the very least, the drug stock’s current dividend payment is well protected. 10 stocks we like better than Pfizer › The average blue chip dividend stock's current yield is somewhere in the ballpark of 3% to 4%. Therefore, to see one paying out nearly 7% of its value is as suspicious as it is impressive. When the ...